When was Scala Biodesign founded?

Scala Biodesign was founded in 2021 and raised its 1st funding round 2 years after it was founded.

Where is Scala Biodesign located?

Scala Biodesign is headquartered in Tel Aviv, Israel.

Who is the current CEO of Scala Biodesign?

Ravit Netzer of Scala Biodesign. They have also founded 1 company.

How many employees does Scala Biodesign have?

As of Jul 31, 2026, the latest employee count at Scala Biodesign is 34.

Is Scala Biodesign a funded company?

Scala Biodesign is a funded company, having raised a total of $21.5M across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Sep 11, 2023.

When was the latest funding round of Scala Biodesign?

Scala Biodesign's latest funding was a $***** Series A round on Mar 31, 2026, with participation from 4 investors.

Where does Scala Biodesign rank among its competitors?

Scala Biodesign ranks 1st amongst 49 active competitors, of which 6 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Scala Biodesign, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of Scala Biodesign?

Scala Biodesign's top competitors include Jade Biosciences, NJ Bio and Liberation Labs. Among them, Scala Biodesign secured the most recent funding round in March, 2026.

Scala Biodesign - 2026 Company Profile, Team, Funding & Competitors

Company Details

It is a company that specializes in computational protein design solutions. They offer unique one-shot solutions to increase value and accelerate protein design processes.

Website: www.scala-bio.com/
Email ID: *****@scala-bio.com

Key Metrics

Founded Year

2021

Location

Tel Aviv, Israel

Stage

Series A

Total Funding

$21.5M in 2 rounds

Latest Funding Round

Series A, Mar 31, 2026, $*****

Investors

TLV Partners & 3 more

Ranked

1^st among 49 active competitors

Employee Count

34 as on Jul 31, 2026

Similar Companies

Jade Biosciences & 49 more

View Scala Biodesign's full profile

Scala Biodesign has raised a total funding of $21.5M over 2 rounds. Its first funding round was on Sep 11, 2023. Its latest funding round was a Series A round on Mar 31, 2026 for $*****. 4 investors participated in its latest round. Scala Biodesign has 4 institutional investors.

Here is the list of recent funding rounds of Scala Biodesign:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 31, 2026	5092829	Series A	1477116	9771329	2390594	8719045
Sep 11, 2023	8924555	Seed	6636077	6113257	TLV Partners	5391795

Access funding benchmarks and valuations. Sign up today!

View details of Scala Biodesign's funding rounds and investors

The founders of Scala Biodesign are Adi Goldenzweig and Ravit Netzer. Ravit Netzer is the CEO of Scala Biodesign.

Here are the details of Scala Biodesign's key team members:

Adi Goldenzweig: Co-Founder & CTO of Scala Biodesign.
Ravit Netzer: Co-Founder & CEO of Scala Biodesign.
Contact Info: 1 email address

View details of Scala Biodesign's Founder profiles and Board Members

Scala Biodesign's employee count trend

Scala Biodesign has 34 employees as of Jul 26. Here is Scala Biodesign's employee count trend over the years:

Employee count trend for Scala Biodesign

Uncover Scala Biodesign's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Scala Biodesign include Jade Biosciences, NJ Bio and Liberation Labs. Here is the list of Top 10 competitors of Scala Biodesign, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Scala Biodesign 2021, Tel Aviv (Israel), Series A	Provider of computational protein design solutions at scale	$21.5M	TLV Partners, Grove Ventures & 2 others	48/100
2nd	Jade Biosciences 2024, Waltham (United States), Public	Biotechnology company offering mass spectrometry-based proteomics services	-	RTW Investments, Versant Ventures & 16 others	45/100
3rd	NJ Bio 2018, North Brunswick (United States), Acquired	Provider of clinical development services	-	-	43/100
4th	Liberation Labs 2022, New York City (United States), Series C	CRO focused on providing fermentation products manufacturing and commercialisation services	$91.6M	Siddhi Capital, Agronomics & 11 others	38/100
5th	Peplib 2017, Boston (United States), Series A	Provider of peptide drug discovery and development services for global pharmaceutical industries	$34.2M	CDH, Cowin Capital & 4 others	37/100
6th	Shantani Proteome Analytics 2010, Pune (India), Seed	Drug discovery and development services using its chemical-proteomics technologies	$988K	India Innovation Fund, Entrepreneurship Development Institute of India ... & 11 others	37/100
7th	Kactus 2018, Shanghai (China), Unfunded	CRO offering chemical proteomics services for preclinical development	-	-	36/100
8th	Krishna Enzytech 1959, Nashik (India), Unfunded	Manufacturer and exporter of natural enzymes, collagens, and proteins	-	-	36/100
9th	ABASIA BIOLABS 2020, Singapore (Singapore), Unfunded	CRO offering chemical proteomics services for preclinical development	-	-	32/100
10th	Kinaxo Biotechnologies 2005, Saarwellingen (Germany), Acquired	Chemical proteomics for cellular target profiling and drug discovery services	$1.38M	HTGF, Mpg & 5 others	31/100